Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and Immunogenicity of SSS40 in Healthy Chinese Subjects
NCT06022536Phase 1Unknown
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Aug 2023
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, randomised, double-blind trial of sss40 in cancer pain (8 arms), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoints: Number of participants with treatment-related adverse events up to 57 days, Peak Plasma Concentration up to 57 days and 2 more. Status: unknown.
02
Drugs
sss40
03
Conditions
cancer pain
Beyond the preview
Go deeper on NCT06022536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06022536.